Premium
Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?
Author(s) -
Eskazan Ahmet Emre
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31682
Subject(s) - dasatinib , medicine , myeloid leukemia , imatinib , tyrosine kinase inhibitor , chronic myelogenous leukemia , adverse effect , oncology , drug holiday , imatinib mesylate , leukemia , immunology , cancer , human immunodeficiency virus (hiv)